Multiple myeloma and amyloidosis begin the same way – in plasma cells, white blood cells that help your immune system. But multiple myeloma (MM) is a rare blood cancer while amyloidosis is a ...

Amyloidosis is a condition associated with multiple myeloma. In amyloidosis, the abnormal plasma cells create many light-chain proteins that can form amyloid deposits.

Multiple myeloma and AL amyloidosis link to plasma cells in the bone marrow. The conditions co-occur in 10–15% of people with MM. Read about the connection.

In this exclusive MedPage Today video, investigator Shahzad Raza, MD, of the Cleveland Clinic Cancer Institute, explains why ...

People often have both amyloidosis and multiple myeloma. Anemia: It's one of the symptoms of multiple myeloma. It happens when too few red blood cells are in your body.

"We want to cure multiple myeloma, one way or another," S. Vincent Rajkumar, MD, chair of the Myeloma Amyloidosis Dysproteinemia Group at Mayo Clinic in Rochester, Minnesota, told MedPage Today ...

Early Phase I results for JNJ-79635322 demonstrated an 86.1% overall response rate in heavily pretreated multiple myeloma patients, including a 100% response in those naïve to B-cell maturation ...

Ríos-Tamayo R, Krsnik I, Gómez-Bueno M, et al. AL amyloidosis and multiple myeloma: A complex scenario in which cardiac involvement remains the key prognostic factor. Life (Basel) . 2023;13(7):1518.

AL amyloidosis is diagnosed in as many as 10 to 15% of patients with myeloma, and 38% of patients with myeloma have Congo red–positive deposits in subcutaneous fat aspirates, bone marrow ...

Multiple myeloma is a cancer of the plasma cells in the bone marrow, but it can impact everything from bone density to kidney function. ... and no signs of a condition called amyloidosis ...

Up to 30% of patients with multiple myeloma have coexisting subclinical primary amyloidosis (Rajkumar SV, Gertz MA, Kyle RA. Primary systemic amyloidosis with delayed progression to multiple ...

"We want to cure multiple myeloma, one way or another," S. Vincent Rajkumar, MD, chair of the Myeloma Amyloidosis Dysproteinemia Group at Mayo Clinic in Rochester, Minnesota, told MedPage Today.